Business Context and Reporting Period
This Form 8-K is filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) with a report date of August 27, 2008, covering an event that occurred on August 12, 2008. The filing discloses the entry into a material definitive agreement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to a specific equity compensation grant:
- Option Grant: 150,000 shares of common stock.
- Exercise Price: $1.47 per share (market value on grant date).
- Service Obligation: Up to 8 hours of consulting services per week for a minimum of one year.
Material Changes
The material change reported is the execution of a Consulting Agreement with Y. Michele Kang. This agreement includes a stock option grant with a three-year vesting schedule:
- 30% of shares vest on the first anniversary.
- 30% of shares vest on the second anniversary.
- 40% of shares vest on the third anniversary.
- Vesting occurs regardless of when the consulting agreement terminates.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of general business risks. The agreement includes a termination clause allowing either party to end the contract with 30 days' notice.
Investor Verification Checklist
- Verify the correct registrant name is Rexahn Pharmaceuticals, Inc., as the input metadata incorrectly listed Opus Genetics, Inc.
- Confirm the total dilution impact of the 150,000 share option grant against the company's current outstanding share count.
- Review the full text of Exhibit 10.1 for additional terms regarding the consulting services and potential conflicts of interest.
- Check subsequent filings for any acceleration of vesting or early termination of the agreement.